A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options.
DocMorris launches approx. CHF 200 million Convertible Bonds due 2029 – Biotech Investments
DocMorris AG / Key word(s): Bond 17-Apr-2024 / 17:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely